NASDAQ:VRNA Verona Pharma (VRNA) Stock Price, News & Analysis $65.46 +0.68 (+1.05%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$65.70 +0.24 (+0.37%) As of 04/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Verona Pharma Stock (NASDAQ:VRNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Verona Pharma alerts:Sign Up Key Stats Today's Range$64.11▼$66.0750-Day Range$53.90▼$69.6352-Week Range$11.39▼$70.40Volume766,895 shsAverage Volume1.23 million shsMarket Capitalization$5.29 billionP/E RatioN/ADividend YieldN/APrice Target$75.43Consensus RatingBuy Company OverviewVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More… Verona Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreVRNA MarketRank™: Verona Pharma scored higher than 39% of companies evaluated by MarketBeat, and ranked 331st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingBuy Consensus RatingVerona Pharma has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerona Pharma has only been the subject of 4 research reports in the past 90 days.Read more about Verona Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verona Pharma are expected to grow in the coming year, from ($1.95) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma is -34.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma is -34.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma has a P/B Ratio of 21.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verona Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.22% of the float of Verona Pharma has been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Verona Pharma has recently decreased by 14.79%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerona Pharma does not currently pay a dividend.Dividend GrowthVerona Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.22% of the float of Verona Pharma has been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Verona Pharma has recently decreased by 14.79%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment1.08 News SentimentVerona Pharma has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Verona Pharma this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for VRNA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verona Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $661,854.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Verona Pharma is held by insiders.Percentage Held by Institutions85.88% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verona Pharma's insider trading history. Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VRNA Stock News HeadlinesVerona Pharma plc (VRNA): Among the Best Multibagger Stocks to Buy According to BillionairesApril 24 at 2:33 AM | msn.comAnalysts Set Expectations for Verona Pharma FY2025 EarningsApril 24 at 2:33 AM | americanbankingnews.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 27, 2025 | Porter & Company (Ad)Verona Pharma plc (NASDAQ:VRNA) Receives $74.67 Consensus Target Price from AnalystsApril 24 at 1:11 AM | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Coverage Initiated at Cantor FitzgeraldApril 22, 2025 | americanbankingnews.comCantor starts Verona at Overweight, says momentum ‘just getting started’April 21, 2025 | markets.businessinsider.comVerona Pharma initiated with an Overweight at Cantor FitzgeraldApril 21, 2025 | markets.businessinsider.comVerona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate UpdateApril 15, 2025 | markets.businessinsider.comSee More Headlines VRNA Stock Analysis - Frequently Asked Questions How have VRNA shares performed this year? Verona Pharma's stock was trading at $46.44 on January 1st, 2025. Since then, VRNA shares have increased by 41.0% and is now trading at $65.46. View the best growth stocks for 2025 here. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) posted its quarterly earnings results on Monday, November, 4th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.12. The firm earned $5.62 million during the quarter, compared to analyst estimates of $2.31 million. Read the conference call transcript. When did Verona Pharma IPO? Verona Pharma (VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. Who are Verona Pharma's major shareholders? Top institutional shareholders of Verona Pharma include Allspring Global Investments Holdings LLC (0.70%), Hennion & Walsh Asset Management Inc. (0.25%), GAMMA Investing LLC (0.14%) and AMI Asset Management Corp (0.05%). Insiders that own company stock include David Zaccardelli, Mark W Hahn, Orbimed Advisors Llc, Kathleen A Rickard, Claire Poll, David R Ebsworth and Martin Edwards. View institutional ownership trends. How do I buy shares of Verona Pharma? Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma investors own include Cisco Systems (CSCO), Philip Morris International (PM), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Home Depot (HD) and CrowdStrike (CRWD). Company Calendar Last Earnings11/04/2024Today4/26/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRNA CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$75.43 High Stock Price Target$93.00 Low Stock Price Target$57.00 Potential Upside/Downside+15.2%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,370,000.00 Net MarginsN/A Pretax Margin-2,698.40% Return on Equity-79.54% Return on Assets-43.49% Debt Debt-to-Equity Ratio0.93 Current Ratio13.03 Quick Ratio12.88 Sales & Book Value Annual Sales$42.28 million Price / Sales125.13 Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book21.12Miscellaneous Outstanding Shares80,820,000Free Float76,103,000Market Cap$5.29 billion OptionableOptionable Beta0.16 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:VRNA) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.